Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 5, 2013, Pages 618-625

  Wang, Jia ^a   Song, Ning ^a   Jiang, Hong ^a   Wang, Jun ^a   Xie, Junxia ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Interleukin 1 ; Iron; Iron regulatory protein 1; Microglia; Neuron; Tumor necrosis factor

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCYSTEINE; CD71 ANTIGEN; FERROPORTIN 1; FERROUS ION; HEPCIDIN; INTERLEUKIN 1BETA; IRON REGULATORY PROTEIN 1; LIPOPOLYSACCHARIDE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NITROGEN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EFFUSION; INTOXICATION; IRON RESPONSIVE ELEMENT; IRON TRANSPORT; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; UPREGULATION; VENTRAL MESENCEPHALIC NERVE CELL;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CATION TRANSPORT PROTEINS; CELLS, CULTURED; HEPCIDINS; INTERLEUKIN-1BETA; IRON; IRON REGULATORY PROTEIN 1; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SALICYLATES; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84874436258     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.01.021     Document Type: Article

References (54)

1. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl. 2000, 277-290.
2. Bartels A.L., Leenders K.L. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov. Disord. 2007, 22:1852-1856.
3. Carvey P.M., Chen E.Y., Lipton J.W., Tong C.W., Chang Q.A., Ling Z.D. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J. Neural Transm. 2005, 112:601-612.
4. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., Tansey K.E., Tansey M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
5. Pott Godoy M.C., Tarelli R., Ferrari C.C., Sarchi M.I., Pitossi F.J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894.
6. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
7. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 1988, 74:199-205.
8. Ke Y., Qian Z.M. Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 2007, 83:149-173.
9. Lee D.W., Andersen J.K. Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis?. J. Neurochem. 2010, 112:332-339.
10. Sian-Hulsmann J., Mandel S., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 2011, 118:939-957.
11. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
12. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 2005, 1:155-157.
13. Jiang H., Song N., Xu H., Zhang S., Wang J., Xie J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. 2010, 20:345-356.
14. Wang J., Jiang H., Xie J.X. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 2007, 25:2766-2772.
15. Song N., Jiang H., Wang J., Xie J.X. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J. Neurosci. Res. 2007, 85:3118-3126.
16. Song N., Wang J., Jiang H., Xie J. Ferroportin1 and hephaestin overexpression attenuate iron-induced oxidative stress in MES23.5 dopaminergic cells. J. Cell. Biochem. 2010, 110:1063-1072.
17. Fahmy M., Young S.P. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem. J. 1993, 296(Pt 1):175-181.
18. Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101:4148-4154.
19. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 2002, 81:301-306.
20. Liu X., Fan X.L., Zhao Y., Luo G.R., Li X.P., Li R., Le W.D. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 2005, 81:653-665.
21. Roque R.S., Caldwell R.B. Isolation and culture of retinal microglia. Curr. Eye Res. 1993, 12:285-290.
22. Zhang S., Wang J., Song N., Xie J., Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 2009, 30:1466-1476.
23. Tenopoulou M., Doulias P.T., Barbouti A., Brunk U., Galaris D. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem. J. 2005, 387:703-710.
24. Song N., Wang J., Jiang H., Xie J. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic. Biol. Med. 2010, 48:332-341.
25. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5:227-231.
26. Zhang X., Surguladze N., Slagle-Webb B., Cozzi A., Connor J.R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 2006, 54:795-804.
27. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J. Hepatol. 2011, 54:173-181.
28. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
29. Rathnasamy G., Ling E.A., Kaur C. Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species. J. Neurosci. 2011, 31:17982-17995.
30. Hackstein H., Morelli A.E., Larregina A.T., Ganster R.W., Papworth G.D., Logar A.J., Watkins S.C., Falo L.D., Thomson A.W. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. 2001, 166:7053-7062.
31. Shackelford R.E., Alford P.B., Xue Y., Thai S.F., Adams D.O., Pizzo S. Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Mol. Pharmacol. 1997, 52:421-429.
32. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15:2057-2072.
33. Ferger B., Teismann P., Earl C.D., Kuschinsky K., Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 360:256-261.
34. Mohanakumar K.P., Muralikrishnan D., Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res. 2000, 864:281-290.
35. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nunez M.T., Garrick M.D., Raisman-Vozari R., Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18578-18583.
36. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009, 89:277-287.
37. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 2002, 133:27-35.
38. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
39. Kato J., Kobune M., Ohkubo S., Fujikawa K., Tanaka M., Takimoto R., Takada K., Takahari D., Kawano Y., Kohgo Y., Niitsu Y. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp. Hematol. 2007, 35:879-887.
40. Christova T., Templeton D.M. Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteins. Mol. Cell. Biochem. 2007, 301:21-32.
41. Gunshin H., Allerson C.R., Polycarpou-Schwarz M., Rofts A., Rogers J.T., Kishi F., Hentze M.W., Rouault T.A., Andrews N.C., Hediger M.A. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett. 2001, 509:309-316.
42. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 2000, 20:627-662.
43. 2) control mammalian iron metabolism by different pathways. Mol. Cell. Biol. 1996, 16:3781-3788.
44. Haile D.J., Rouault T.A., Harford J.B., Kennedy M.C., Blondin G.A., Beinert H., Klausner R.D. Cellular regulation of the iron-responsive element binding protein: disassembly of the cubane iron-sulfur cluster results in high-affinity RNA binding. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11735-11739.
45. Brix B., Mesters J.R., Pellerin L., Johren O. Endothelial cell-derived nitric oxide enhances aerobic glycolysis in astrocytes via HIF-1alpha-mediated target gene activation. J. Neurosci. 2012, 32:9727-9735.
46. Chowdhury R., Godoy L.C., Thiantanawat A., Trudel L.J., Deen W.M., Wogan G.N. Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1alpha stabilization in colon carcinoma cells. Chem. Res. Toxicol. 2012, 25:2194-2202.
47. Niecknig H., Tug S., Reyes B.D., Kirsch M., Fandrey J., Berchner-Pfannschmidt U. Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia. Free Radic. Res. 2012, 46:705-717.
48. Tacchini L., Gammella E., De Ponti C., Recalcati S., Cairo G. Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J. Biol. Chem. 2008, 283:20674-20686.
49. Luo Q.Q., Wang D., Yu M.Y., Zhu L. Effect of hypoxia on the expression of iron regulatory proteins 1 and the mechanisms involved. IUBMB Life 2011, 63:120-128.
50. Stys A., Galy B., Starzynski R.R., Smuda E., Drapier J.C., Lipinski P., Bouton C. Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide. J. Biol. Chem. 2011, 286:22846-22854.
51. Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., McMillian M.K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 1995, 704:112-116.
52. Dobrovolskaia M.A., Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 2002, 4:903-914.
53. Crichton R.R., Wilmet S., Legssyer R., Ward R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J. Inorg. Biochem. 2002, 91:9-18.
54. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005, 58:963-967.